8-K: Theravance Completes Pivotal Phase 3 CYPRESS Enrollment

Theravance Biopharma announced the completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study for ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA).

Summary

• Theravance Biopharma has completed enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study for ampreloxetine.
• The study targets symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder.
• nOH affects approximately 80% of MSA patients, which totals about 40,000 patients in the U.S. alone.
• Ampreloxetine is an investigational, once-daily, selective norepinephrine reuptake inhibitor designed to address the underlying cause of nOH.
• Topline results from the Phase 3 CYPRESS trial are anticipated in Q1 2026.
• If successful, the company plans for an expedited New Drug Application (NDA) submission and will request priority FDA review.
• Ampreloxetine has Orphan Drug Designation in the U.S. for symptomatic nOH in patients with MSA.
• The CYPRESS study is a global, randomized-withdrawal study, with patients enrolled across four continents in the 12-week open-label portion.
• Responders from the open-label portion will be randomized 1:1 to continue ampreloxetine or switch to placebo for eight weeks in the randomized-withdrawal portion.
• The primary endpoint is the change in orthostatic hypotension symptom assessment (OHSA) composite score from randomized-withdrawal baseline to Week 8.

Sentiment

Score: 8

Explanation: The completion of enrollment in a pivotal Phase 3 study for a drug addressing a significant unmet medical need, coupled with Orphan Drug Designation and plans for expedited regulatory review, represents a strong positive milestone for the company. While a previous study had mixed results, the current study is more targeted based on those insights, indicating a de-risked approach. The anticipation of topline data in Q1 2026 provides a clear near-term catalyst.

Positives

• Completion of enrollment in the pivotal Phase 3 CYPRESS study marks a significant milestone for ampreloxetine.
• Ampreloxetine has the potential to be the first therapy to provide durable benefit for the 40,000 U.S. patients with symptomatic nOH due to MSA, addressing a critical unmet medical need.
• The drug has been granted Orphan Drug Designation in the U.S., highlighting the severity and rarity of the condition.
• Previous Study 0170 showed compelling improvement in OHSA composite score without worsening supine hypertension in MSA patients.
• The company is planning for an expedited NDA submission and will request priority FDA review if data are supportive, potentially accelerating market access.
• The CYPRESS randomized withdrawal trial was designed with insights from Study 0170, aiming for a de-risked program.

Negatives

• Previous Phase 3 Study 0169 did not meet its primary endpoint for the overall population of patients with symptomatic nOH, which included Parkinson's disease, pure autonomic failure, and MSA patients.

Risks

• Delays or difficulties in commencing, enrolling, or completing clinical studies.
• The potential that results from clinical or non-clinical studies indicate product candidates are unsafe, ineffective, or not differentiated.
• Risks of decisions from regulatory authorities that are unfavorable to the company.
• Dependence on third parties to conduct clinical studies.
• Delays or failure to achieve and maintain regulatory approvals for product candidates.
• Risks of collaborating with or relying on third parties to discover, develop, manufacture, and commercialize products.
• Risks associated with establishing and maintaining sales, marketing, and distribution capabilities.
• The ability of the company to protect and enforce its intellectual property rights.
• Volatility and fluctuations in the trading price and volume of the company's shares.
• General economic and market conditions.
• The status of patent infringement litigation initiated by the Company and its partner against certain generic companies in federal district courts.

Future Outlook

Theravance Biopharma anticipates reporting topline data from the Phase 3 CYPRESS trial in Q1 2026. If the data are supportive, the company plans for an expedited NDA submission and will request priority FDA review. Ampreloxetine has the potential to be the first therapy to provide durable benefit for patients with symptomatic nOH due to MSA.

Management Comments

• Dr. Horacio Kaufmann, F. B. Axelrod Professor of Neurology and Professor of Medicine at NYU Grossman School of Medicine, stated: "Ampreloxetine is designed to address the underlying cause of nOH. In Study 0170, it showed compelling improvement in OHSA composite score without worsening supine hypertension. If these benefits are confirmed, I would expect to use ampreloxetine in the majority of my patients living with nOH due to MSA. I am encouraged that enrollment in CYPRESS, the first randomized-withdrawal trial designed specifically for the MSA population, has been completed, and I look forward to seeing the data early next year."
• Bine Miller, Ph.D., Head of Development at Theravance Biopharma, stated: "Completing enrollment in CYPRESS marks a major step toward bringing this potentially transformative therapy to patients with symptomatic nOH due to MSA – an underserved patient population in dire need for a new, effective and durable treatment with a favorable safety profile. Ampreloxetine is intended to target the root cause driving MSA-associated nOH by selectively inhibiting norepinephrine reuptake, and demonstrated benefit in this patient population in Study 0170. The CYPRESS randomized withdrawal trial was designed with insights from Study 0170, and we are confident that, along with our careful study execution, this derisked program strongly positions us to evaluate ampreloxetine's full potential in this patient population."

Industry Context

Neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA) represents a significant unmet medical need. MSA is a rare and progressive neurodegenerative disorder affecting approximately 40,000 patients in the U.S., with 70-90% experiencing nOH symptoms. Current therapies often fail to provide lasting symptom relief, require frequent dosing, and carry a boxed warning for supine hypertension. Ampreloxetine aims to address the underlying cause of nOH, potentially offering a more effective and durable treatment option in an area lacking specialized therapies.

Comparison to Industry Standards

• Current therapies for nOH often fail to provide lasting symptom relief, require frequent dosing, and carry a boxed warning for supine hypertension.
• Ampreloxetine, in Study 0170, showed compelling improvement in OHSA composite score without worsening supine hypertension, differentiating it from existing treatments.
• The CYPRESS study is highlighted as the first randomized-withdrawal trial designed specifically for the MSA population, indicating a targeted approach compared to broader nOH studies.

Legal Proceedings

• The company is involved in patent infringement litigation initiated by the Company and its partner against certain generic companies in federal district courts.

Stakeholder Impact

• **Shareholders:** Potential for significant value creation if ampreloxetine is approved, given the unmet need and market opportunity. The completion of enrollment is a de-risking event.
• **Patients with nOH due to MSA:** Potential access to a new, effective, and durable treatment option for a debilitating condition with limited current therapies.
• **Medical Community:** A new therapeutic option could significantly improve patient care and outcomes for a challenging neurodegenerative disorder.
• **Regulatory Authorities:** Will be reviewing data for a potential priority review and expedited approval process.

Next Steps

• Report topline data from the Phase 3 CYPRESS trial in Q1 2026.
• Prepare for an expedited NDA submission following successful results.
• Plan to request priority FDA review for ampreloxetine, if data are supportive.

Key Dates

Recommendation

The completion of enrollment in a pivotal Phase 3 study is a positive operational milestone, de-risking the clinical development pathway for ampreloxetine. The drug targets a significant unmet medical need with Orphan Drug Designation and has shown promising subgroup data in previous trials. However, the ultimate success hinges on the topline results expected in Q1 2026. While the outlook is positive, a 'hold' recommendation is appropriate until efficacy and safety data are released, as clinical trial outcomes always carry inherent risks. Investors should monitor the upcoming data release for a more definitive assessment.

Keywords

Theravance Biopharma, Ampreloxetine, CYPRESS study, Phase 3, Neurogenic Orthostatic Hypotension, nOH, Multiple System Atrophy, MSA, Orphan Drug Designation, Clinical Trial, Drug Development, Biopharma, Norepinephrine Reuptake Inhibitor, NDA Submission, FDA Review